Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Embolism and Thrombosis

ClinicalTrials.gov lists 3,269 trials for Embolism and Thrombosis or a narrower condition beneath it. Bayer has the most among industry and government lead sponsors, with 77.

MeSH D016769 Cardiovascular Diseases C14
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 144 Phase 1/2 Phase 1/2 42 Phase 2 Phase 2 225 Phase 2/3 Phase 2/3 52 Phase 3 Phase 3 398 Phase 4 Phase 4 328 Not applicable Not applicable 756 Observational Observational 1,323 Phase 1 Phase 1 144 Phase 1/2 Phase 1/2 42 Phase 2 Phase 2 225 Phase 2/3 Phase 2/3 52 Phase 3 Phase 3 398 Phase 4 Phase 4 328 Not applicable Not applicable 756 Observational Observational 1,323

Trials per phase (log scale)

1 more section with rows

52 of the 3,269 trials are tagged with Embolism and Thrombosis itself; the rest are tagged with a narrower condition beneath it.

Get the Embolism and Thrombosis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Embolism and Thrombosis trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 209

1990: 2 trials (Observational 2) 1991: 2 trials (Observational 2) 1992: 5 trials (Observational 3, Phase 3 2) 1993: 3 trials (Observational 1, Not applicable 1, Phase 3 1) 1994: 6 trials (Observational 4, Phase 4 1, Phase 3 1) 1995: 3 trials (Observational 1, Not applicable 1, Phase 3 1) 1996: 7 trials (Observational 4, Not applicable 1, Phase 3 2) 1997: 2 trials (Not applicable 1, Phase 4 1) 1998: 10 trials (Observational 3, Phase 4 1, Phase 3 5, Phase 1 1) 1999: 11 trials (Observational 3, Not applicable 2, Phase 4 3, Phase 3 3) 2000: 9 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 2 4) 2001: 15 trials (Observational 7, Not applicable 1, Phase 4 2, Phase 3 2, Phase 2 2, Phase 1 1) 2002: 37 trials (Observational 8, Not applicable 3, Phase 4 9, Phase 3 5, Phase 2/3 1, Phase 2 9, Phase 1 2) 2003: 31 trials (Observational 5, Not applicable 3, Phase 4 6, Phase 3 10, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2004: 51 trials (Observational 13, Not applicable 5, Phase 4 5, Phase 3 13, Phase 2/3 3, Phase 2 11, Phase 1 1) 2005: 72 trials (Observational 20, Not applicable 12, Phase 4 12, Phase 3 8, Phase 2/3 2, Phase 2 11, Phase 1/2 2, Phase 1 5) 2006: 114 trials (Observational 27, Not applicable 18, Phase 4 12, Phase 3 31, Phase 2/3 7, Phase 2 13, Phase 1/2 1, Phase 1 5) 2007: 109 trials (Observational 27, Not applicable 14, Phase 4 11, Phase 3 32, Phase 2/3 3, Phase 2 17, Phase 1 5) 2008: 103 trials (Observational 32, Not applicable 21, Phase 4 9, Phase 3 27, Phase 2/3 3, Phase 2 5, Phase 1/2 3, Phase 1 3) 2009: 113 trials (Observational 35, Not applicable 18, Phase 4 14, Phase 3 20, Phase 2/3 6, Phase 2 10, Phase 1/2 2, Phase 1 8) 2010: 110 trials (Observational 38, Not applicable 21, Phase 4 18, Phase 3 18, Phase 2/3 1, Phase 2 8, Phase 1/2 3, Phase 1 3) 2011: 123 trials (Observational 51, Not applicable 29, Phase 4 14, Phase 3 12, Phase 2/3 2, Phase 2 6, Phase 1/2 3, Phase 1 6) 2012: 131 trials (Observational 56, Not applicable 27, Phase 4 9, Phase 3 18, Phase 2/3 2, Phase 2 12, Phase 1/2 3, Phase 1 4) 2013: 128 trials (Observational 50, Not applicable 24, Phase 4 18, Phase 3 15, Phase 2/3 2, Phase 2 14, Phase 1/2 2, Phase 1 3) 2014: 142 trials (Observational 53, Not applicable 43, Phase 4 16, Phase 3 12, Phase 2/3 1, Phase 2 7, Phase 1/2 1, Phase 1 9) 2015: 155 trials (Observational 66, Not applicable 31, Phase 4 19, Phase 3 13, Phase 2/3 2, Phase 2 13, Phase 1/2 3, Phase 1 8) 2016: 149 trials (Observational 66, Not applicable 34, Phase 4 12, Phase 3 15, Phase 2/3 2, Phase 2 2, Phase 1/2 3, Phase 1 15) 2017: 170 trials (Observational 67, Not applicable 50, Phase 4 21, Phase 3 13, Phase 2 12, Phase 1 7) 2018: 151 trials (Observational 76, Not applicable 35, Phase 4 12, Phase 3 11, Phase 2/3 1, Phase 2 8, Phase 1/2 2, Phase 1 6) 2019: 164 trials (Observational 72, Not applicable 42, Phase 4 14, Phase 3 12, Phase 2 11, Phase 1/2 2, Phase 1 11) 2020: 209 trials (Observational 113, Not applicable 42, Phase 4 13, Phase 3 21, Phase 2/3 2, Phase 2 10, Phase 1/2 1, Phase 1 7) 2021: 174 trials (Observational 78, Not applicable 47, Phase 4 14, Phase 3 14, Phase 2/3 2, Phase 2 7, Phase 1/2 5, Phase 1 7) 2022: 160 trials (Observational 72, Not applicable 49, Phase 4 15, Phase 3 12, Phase 2/3 3, Phase 2 6, Phase 1 3) 2023: 149 trials (Observational 75, Not applicable 46, Phase 4 9, Phase 3 8, Phase 2 8, Phase 1 3) 2024: 145 trials (Observational 68, Not applicable 43, Phase 4 12, Phase 3 10, Phase 2/3 3, Phase 2 2, Phase 1/2 1, Phase 1 6) 2025: 143 trials (Observational 53, Not applicable 50, Phase 4 12, Phase 3 12, Phase 2/3 2, Phase 2 7, Phase 1/2 1, Phase 1 6)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 139
2025 143
2024 145
2023 149
2022 160
2021 174
2020 209
2019 164
2018 151
2017 170

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 160 trials starting in 2026 and about 150 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 195 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 2,053 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Embolism and Thrombosis trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 144
Phase 1/2 42
Phase 2 225
Phase 2/3 52
Phase 3 398
Phase 4 328
Not applicable 756
Observational 1,323
Expanded access 1

How many Embolism and Thrombosis trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 108
Recruiting 336
Enrolling by invitation 16
Active, not recruiting 78
Completed 1,846

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Embolism and Thrombosis trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Bayer 77
Bristol-Myers Squibb 39
Boehringer Ingelheim 29
Sanofi 28
National Heart, Lung, and Blood Institute (NHLBI) 22

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Embolism and Thrombosis? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Rivaroxaban 165
LOVENOX 141
(LMW)heparin 35
Innohep 27
Edoxaban 26

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Warfarin VKA 94
Apixaban IR 94
EC Aspirin 67
ranibizumab PRN 50
Fragmin P Forte (dalteparin sodium) 36

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Embolism and Thrombosis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,640 90
Injury, poisoning, accidents, etc. 1,346 1
Genitourinary system 1,141 1
ATRIAL FIBRILLATION 1,054 6
Digestive system 1,016 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: publications, prevalence, and rare-disease identity.

Browse all condition evidence pages